Disease-modifying therapies for Alzheimer disease
暂无分享,去创建一个
[1] F. Gage,et al. Continuous infusion of nerve growth factor prevents basal forebrain neuronal death after fimbria fornix transection. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[2] P. Aisen,et al. A Phase II study targeting amyloid-β with 3APS in mild-to-moderate Alzheimer disease , 2006, Neurology.
[3] Jonas Persson,et al. Reduced functional brain activity response in cognitively intact apolipoprotein E epsilon4 carriers. , 2006, Brain : a journal of neurology.
[4] D. Bennett,et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. , 2005, The New England journal of medicine.
[5] P. Gressens,et al. Positive allosteric modulators of AMPA receptors are neuroprotective against lesions induced by an NMDA agonist in neonatal mouse brain , 2003, Brain Research.
[6] Robert A. Dean,et al. Effects of a γ-secretase inhibitor in a randomized study of patients with Alzheimer disease , 2006, Neurology.
[7] Xudong Huang,et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloidogenesis , 2004, Experimental Gerontology.
[8] M. Chong,et al. Preclinical Alzheimer's disease: diagnosis and prediction of progression , 2005, The Lancet Neurology.
[9] C. Jack,et al. Comparison of memory fMRI response among normal, MCI, and Alzheimer’s patients , 2003, Neurology.
[10] G. Bartzokis,et al. White matter structural integrity in healthy aging adults and patients with Alzheimer disease: a magnetic resonance imaging study. , 2003, Archives of neurology.
[11] Michela Gallagher,et al. A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.
[12] M. Sabbagh,et al. Do cholinergic therapies have disease-modifying effects in Alzheimer’s disease? , 2006, Alzheimer's & Dementia.
[13] K. Davis,et al. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial. , 2003, JAMA.
[14] G. Small,et al. Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease. , 2002, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[15] H. Arai,et al. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease , 2005, Annals of neurology.
[16] M. Gallagher,et al. A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.
[17] Patrizia Mecocci,et al. Conversion of MCI to dementia: Role of proton magnetic resonance spectroscopy , 2006, Neurobiology of Aging.
[18] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[19] J. Morris,et al. Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.
[20] C. Morissette,et al. Targeting soluble Aβ peptide with Tramiprosate for the treatment of brain amyloidosis , 2007, Neurobiology of Aging.
[21] Yaakov Stern,et al. PET Network Abnormalities and Cognitive Decline in Patients with Mild Cognitive Impairment , 2006, Neuropsychopharmacology.
[22] R. Killiany,et al. Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.
[23] W. Markesbery,et al. Increased levels of 4-hydroxynonenal and acrolein, neurotoxic markers of lipid peroxidation, in the brain in Mild Cognitive Impairment and early Alzheimer's disease , 2006, Neurobiology of Aging.
[24] E. Tangalos,et al. Neuropathologic features of amnestic mild cognitive impairment. , 2006, Archives of neurology.
[25] E. Masliah,et al. The neuroprotective effects of Cerebrolysin™ in a transgenic model of Alzheimer’s disease are associated with improved behavioral performance , 2003, Journal of Neural Transmission.
[26] H. Cai,et al. Amyloid β peptide load is correlated with increased β-secretase activity in sporadic Alzheimer's disease patients , 2004 .
[27] D. Pollen,et al. Familial Alzheimer disease: Decreases in CSF Aβ42 levels precede cognitive decline , 2005, Neurology.
[28] P. Soubrié,et al. Effect of the neuroprotective compound SR57746A on nerve growth factor synthesis in cultured astrocytes from neonatal rat cortex , 1999, British journal of pharmacology.
[29] A. Hofman,et al. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.
[30] M. Citron,et al. Strategies for disease modification in Alzheimer's disease , 2004, Nature Reviews Neuroscience.
[31] D. Bennett,et al. Loss and atrophy of layer II entorhinal cortex neurons in elderly people with mild cognitive impairment , 2001, Annals of neurology.
[32] Virginia M. Y. Lee,et al. Lithium Reduces Tau Phosphorylation by Inhibition of Glycogen Synthase Kinase-3* , 1997, The Journal of Biological Chemistry.
[33] Takashi Morihara,et al. Selective inhibition of Aβ42 production by NSAID R‐enantiomers , 2002 .
[34] S. Wisniewski,et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.
[35] I. Kola,et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. , 2001, Human molecular genetics.
[36] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[37] H. Tuokko,et al. Five-year follow-up of cognitive impairment with no dementia. , 2003, Archives of neurology.
[38] T. Asano,et al. Arundic acid (ONO-2506) ameliorates delayed ischemic brain damage by preventing astrocytic overproduction of S100B. , 2005, Current drug targets. CNS and neurological disorders.
[39] R. Berry,et al. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[40] W. Oertel,et al. Treatment with the selective muscarinic ml agonist talsaclidine decreases cerebrospinal fluid levels of Aβ42 in patients with Alzheimer's disease , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[41] K. Blennow,et al. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.
[42] F. LaFerla,et al. M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice , 2006, Neuron.
[43] K. Blennow,et al. CSF markers for incipient Alzheimer's disease , 2003, The Lancet Neurology.
[44] R. Mayeux,et al. Hyperinsulinemia and risk of Alzheimer disease , 2004, Neurology.
[45] Young-don Kwak,et al. Stem cell strategies for Alzheimer's disease therapy. , 2006, Panminerva medica.
[46] Charles D. Smith,et al. Neuropathologic substrate of mild cognitive impairment. , 2006, Archives of neurology.
[47] J. Kaye,et al. Safety and Acceptability of the Research Lumbar Puncture , 2005, Alzheimer disease and associated disorders.
[48] S. Yamazaki,et al. The γ-Secretase Inhibitor N-[N-(3,5-Difluorophenacetyl)-l-alanyl]-S-phenylglycine t-butyl Ester Reduces Aβ Levels in Vivo in Plasma and Cerebrospinal Fluid in Young (Plaque-Free) and Aged (Plaque-Bearing) Tg2576 Mice , 2003, Journal of Pharmacology and Experimental Therapeutics.
[49] M. Mattson,et al. Folic Acid Deficiency and Homocysteine Impair DNA Repair in Hippocampal Neurons and Sensitize Them to Amyloid Toxicity in Experimental Models of Alzheimer's Disease , 2002, The Journal of Neuroscience.
[50] B. Winblad,et al. Low blood pressure and risk of dementia in the Kungsholmen project: a 6-year follow-up study. , 2003, Archives of neurology.
[51] B. Caffo,et al. Familial risk for Alzheimer's disease alters fMRI activation patterns. , 2006, Brain : a journal of neurology.
[52] C. Masters,et al. Treatment with a Copper-Zinc Chelator Markedly and Rapidly Inhibits β-Amyloid Accumulation in Alzheimer's Disease Transgenic Mice , 2001, Neuron.
[53] J. Warter,et al. Effect of the nonpeptide neurotrophic compound SR 57746A on the phenotypic survival of purified mouse motoneurons , 1999, British journal of pharmacology.
[54] H. Feldman,et al. Cholesterol in Alzheimer's disease , 2005, The Lancet Neurology.
[55] Robert A. Copeland,et al. Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors* , 2000, The Journal of Biological Chemistry.
[56] Alex Kiss,et al. Neuropsychological tests accurately predict incident Alzheimer disease after 5 and 10 years , 2005, Neurology.
[57] PhD Marie-Françoise Chesselet MD. Molecular Mechanisms of Neurodegenerative Diseases , 2001, Contemporary Clinical Neuroscience.
[58] J. Schneider,et al. Neuropathology of older persons without cognitive impairment from two community-based studies , 2006, Neurology.
[59] J. Baron,et al. Mild cognitive impairment , 2003, Neurology.
[60] J. Trojanowski,et al. Early Vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of Alzheimer's disease , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[61] P. Soubrié,et al. SR 57746A: An Orally Active Non‐Peptide Compound with Neurotrophic and Neuroprotective Effects , 1997 .
[62] Nick C Fox,et al. Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial , 2005, Neurology.
[63] C. Jack,et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. , 2004, Archives of neurology.
[64] C. Jack,et al. Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.
[65] T. Montine,et al. Quantitative in vivo biomarkers of oxidative damage and their application to the diagnosis and management of Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[66] E. Kaplan,et al. The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort. , 1995, Archives of neurology.
[67] M. Youdim,et al. Rasagiline: Neurodegeneration, neuroprotection, and mitochondrial permeability transition , 2005, Journal of neuroscience research.
[68] J. Schneider,et al. Parahippocampal tau pathology in healthy aging, mild cognitive impairment, and early Alzheimer's disease , 2002, Annals of neurology.
[69] R. Petersen,et al. Mild cognitive impairment , 2006, The Lancet.
[70] L. Thal,et al. Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology , 2003, Neurology.
[71] J. Morrow,et al. Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.
[72] A. Smith,et al. Low thyroid-stimulating hormone as an independent risk factor for Alzheimer disease , 2004, Neurology.
[73] E. Levin. Nicotinic receptor subtypes and cognitive function. , 2002, Journal of neurobiology.
[74] C. DeCarli,et al. A pilot study of vitamins to lower plasma homocysteine levels in Alzheimer disease. , 2003, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[75] A. Mackinnon,et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. , 2003, Archives of neurology.
[76] A. Toga,et al. Three-dimensional patterns of hippocampal atrophy in mild cognitive impairment. , 2006, Archives of neurology.
[77] Kiralee M. Hayashi,et al. Conversion of mild cognitive impairment to Alzheimer disease predicted by hippocampal atrophy maps. , 2006, Archives of neurology.
[78] Giuseppe Scotti,et al. A whole brain MR spectroscopy study from patients with Alzheimer's disease and mild cognitive impairment , 2005, NeuroImage.
[79] C. Patterson,et al. Moderately Elevated Plasma Homocysteine, Methylenetetrahydrofolate Reductase Genotype, and Risk for Stroke, Vascular Dementia, and Alzheimer Disease in Northern Ireland , 2002, Stroke.
[80] G. Cole,et al. Selective inhibition of Abeta42 production by NSAID R-enantiomers. , 2002, Journal of neurochemistry.
[81] B L Holman,et al. Preclinical prediction of Alzheimer's disease using SPECT , 1998, Neurology.
[82] C. Jack,et al. Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment , 2004, Journal of internal medicine.
[83] C. Jack,et al. Qualitative estimates of medial temporal atrophy as a predictor of progression from mild cognitive impairment to dementia. , 2007, Archives of neurology.
[84] J. Touchon,et al. Classification criteria for mild cognitive impairment , 2001, Neurology.
[85] B. Winblad,et al. The course of cognitive impairment in preclinical Alzheimer disease: three- and 6-year follow-up of a population-based sample. , 2000, Archives of neurology.
[86] Alan A. Wilson,et al. In-vivo imaging of Alzheimer disease beta-amyloid with [11C]SB-13 PET. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[87] A. Kurz,et al. Progression to Dementia in Clinical Subtypes of Mild Cognitive Impairment , 2006, Dementia and Geriatric Cognitive Disorders.
[88] J. Haines,et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. , 1993, Science.
[89] H. Soininen,et al. Hippocampus and entorhinal cortex in mild cognitive impairment and early AD , 2004, Neurobiology of Aging.
[90] L. Thal,et al. Early and persistent alterations in prefrontal cortex MAO A and B in Alzheimer's disease , 2003, Journal of Neural Transmission.
[91] C. Masters,et al. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease , 1999, Annals of neurology.
[92] J. Cummings. Cholinesterase inhibitors: A new class of psychotropic compounds. , 2000, The American journal of psychiatry.
[93] A. Korten,et al. The prevalence of dementia: A quantitative integration of the literature , 1987, Acta psychiatrica Scandinavica.
[94] J. Riggs,et al. Alzheimer’s research: Can it help save our nation’s entitlement programs? , 2005, Alzheimer's & Dementia.
[95] K. Lunetta,et al. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease , 2007, Nature Genetics.
[96] R. Green,et al. Estimating risk curves for first-degree relatives of patients with Alzheimer’s disease: The REVEAL study , 2004, Genetics in Medicine.
[97] G. Schellenberg,et al. Head circumference and incident Alzheimer’s disease , 2001, Neurology.
[98] Jonas Persson,et al. Reduced functional brain activity response in cognitively intact apolipoprotein E ε4 carriers , 2006 .
[99] Steven G Potkin,et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.
[100] A. Fisher,et al. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease. , 2002, Journal of molecular neuroscience : MN.
[101] K. Sugaya. Possible use of autologous stem cell therapies for Alzheimer's disease. , 2005, Current Alzheimer research.
[102] S Shimohama,et al. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. , 1997, Alzheimer disease and associated disorders.
[103] J. Kornhuber,et al. Memantine in moderate-to-severe Alzheimer's disease. , 2003, The New England journal of medicine.
[104] P. Tariot,et al. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. , 2006, Neurology.
[105] C. Parsons,et al. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist—a review of preclinical data , 1999, Neuropharmacology.
[106] L. Cohen,et al. The Molecular Basis of Hypopituitarism , 1998, Hormone Research in Paediatrics.
[107] N. Fox,et al. A decade of pre-diagnostic assessment in a case of familial Alzheimer’s disease: tracking progression from asymptomatic to MCI and dementia , 2005, Neurocase.
[108] A. Convit,et al. Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.
[109] J. Cummings. Clinical evaluation as a biomarker for Alzheimer's disease. , 2006, Journal of Alzheimer's disease : JAD.
[110] B. Winblad,et al. Clinical trials in mild cognitive impairment: lessons for the future , 2005, Journal of Neurology, Neurosurgery & Psychiatry.
[111] Mark S. Cohen,et al. Patterns of brain activation in people at risk for Alzheimer's disease. , 2000, The New England journal of medicine.
[112] Felice Sun,et al. Brain imaging evidence of preclinical Alzheimer's disease in normal aging , 2006, Annals of neurology.
[113] E. Tangalos,et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. , 2006, Archives of neurology.
[114] E G Tangalos,et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease , 2000, Neurology.
[115] Yu-Min Kuo,et al. Increased Aβ Peptides and Reduced Cholesterol and Myelin Proteins Characterize White Matter Degeneration in Alzheimer's Disease† , 2002 .
[116] G. Dunbar,et al. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects. , 2006, CNS drug reviews.
[117] A. Hofman,et al. Plasma Aβ1–40 and Aβ1–42 and the risk of dementia: a prospective case-cohort study , 2006, The Lancet Neurology.
[118] P. Thompson,et al. PET of brain amyloid and tau in mild cognitive impairment. , 2006, The New England journal of medicine.
[119] M. Hennerici,et al. Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[120] E. Nisenbaum,et al. LY404187: a novel positive allosteric modulator of AMPA receptors. , 2006, CNS drug reviews.
[121] C. Bergmann,et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[122] B. Martin,et al. Cardiovascular and Cerebrovascular Events in the Randomized, Controlled Alzheimer's Disease Anti-Inflammatory Prevention Trial (ADAPT) , 2006, PLoS clinical trials.
[123] H. Feldman,et al. Treatment of Alzheimer's disease; current status and new perspectives , 2003, The Lancet Neurology.
[124] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[125] M. Reger,et al. Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. , 2005, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[126] C. Jack,et al. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD , 2003, Neurology.
[127] M. Mesulam,et al. Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment. , 2003, Archives of neurology.
[128] Sung-Cheng Huang,et al. Serotonin 1A receptors in the living brain of Alzheimer's disease patients. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[129] W R Markesbery,et al. Risk factors for transitions from normal to mild cognitive impairment and dementia , 2006, Neurology.
[130] Christina A. Wilson,et al. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. , 2003, Nature.
[131] Nick C Fox,et al. Using serial registered brain magnetic resonance imaging to measure disease progression in Alzheimer disease: power calculations and estimates of sample size to detect treatment effects. , 2000, Archives of neurology.
[132] Eric M Reiman,et al. The Role of Biomarkers in Clinical Trials for Alzheimer Disease , 2006, Alzheimer disease and associated disorders.
[133] R. Havlik,et al. Midlife blood pressure and dementia: the Honolulu–Asia aging study☆ , 2000, Neurobiology of Aging.
[134] A. Nordberg. Mechanisms Behind the Neuroprotective Actions of Cholinesterase Inhibitors in Alzheimer Disease , 2006, Alzheimer disease and associated disorders.
[135] W. A. Pedersen,et al. Insulin resistance contributes to aberrant stress responses in the Tg2576 mouse model of Alzheimer's disease , 2004, Neurobiology of Disease.
[136] Roger N Gunn,et al. In-vivo measurement of activated microglia in dementia , 2001, The Lancet.
[137] J. Cummings,et al. Mild Cognitive Impairment is Associated With Characteristic Neuropsychiatric Symptoms , 2004, Alzheimer disease and associated disorders.
[138] Christina A. Wilson,et al. GSK-3α regulates production of Alzheimer's disease amyloid-β peptides , 2003, Nature.
[139] Trey Sunderland,et al. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. , 2003, JAMA.
[140] Douglas Walker,et al. Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. , 2002, Biochemistry.
[141] Hilkka Soininen,et al. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study , 2006, The Lancet Neurology.
[142] J. Hodges,et al. Limbic hypometabolism in Alzheimer's disease and mild cognitive impairment , 2003, Annals of neurology.
[143] Gina N. LaRossa,et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans , 2006, Annals of neurology.
[144] H. Cai,et al. Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[145] M. Sofroniew,et al. Nerve growth factor signaling, neuroprotection, and neural repair. , 2001, Annual review of neuroscience.
[146] Ge Li,et al. Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. , 2006, Archives of neurology.
[147] D. Bennett,et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.
[148] J. Dichgans,et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: A 26‐week randomized, placebo‐controlled, double‐blind trial , 2002, Annals of neurology.
[149] C B Hall,et al. Low blood pressure and the risk of dementia in very old individuals , 2003, Neurology.
[150] W. Liao,et al. Inflammation in Alzheimer's Disease , 1999, Science.
[151] Y. Stern,et al. An association between head circumference and Alzheimer's disease in a population-based study of aging and dementia , 1997, Neurology.
[152] F. Jessen,et al. Multicenter assessment of reliability of cranial MRI , 2006, Neurobiology of Aging.
[153] G. Bartzokis,et al. Heterogeneous age-related breakdown of white matter structural integrity: implications for cortical “disconnection” in aging and Alzheimer’s disease , 2004, Neurobiology of Aging.
[154] R. Petersen,et al. Development of Cognitive Instruments for Use in Clinical Trials of Antidementia Drugs: Additions to the Alzheimer's Disease Assessment Scale That Broaden Its Scope , 1997, Alzheimer disease and associated disorders.
[155] A Hofman,et al. Effect of smoking on global cognitive function in nondemented elderly , 2004, Neurology.
[156] Agneta Nordberg,et al. PET imaging of amyloid in Alzheimer's disease , 2004, The Lancet Neurology.
[157] P Woodbury,et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. , 1997, The New England journal of medicine.
[158] R. Mayeux,et al. Stroke and the risk of Alzheimer disease. , 2003, Archives of neurology.
[159] J. Troncoso,et al. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease , 2003, Annals of neurology.